Key result
Mibefradil was effective for the symptomatic treatment of hypertension and stable angina pectoris but was withdrawn due to drug interactions at the cytochrome P-450 3A4 enzyme.
Population
Patients with hypertension and stable angina pectoris
Design
Review
Authors
Loading...
Mibefradil's CYP3A4 interactions warrant ongoing caution; leaves open selective T-channel blockade for hypertension and angina research.
Mibefradil showed promise for hypertension and angina but was withdrawn due to CYP3A4 interactions, leaving T-channel blockade as an area for future drug development.
Vring et al. (1999) conducted a review in Hypertension and stable angina pectoris. Mibefradil was evaluated. Mibefradil was effective for the symptomatic treatment of hypertension and stable angina pectoris but was withdrawn due to drug interactions at the cytochrome P-450 3A4 enzyme.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: